4DMedical

4DMedical Equity

The The Equity of 4DMedical (4DX.AX) as of Nov 5, 2026 is 170.16 M AUD. In the previous year, The Equity was 64.24 M AUD — a change of 164.91% (higher).

Equity

170.16 MAUD

YoY

164.91%

Last updated:

In 2026, 4DMedical's equity was 170.16 M AUD, a 164.91% increase from the 64.24 M AUD equity in the previous year.

The 4DMedical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
4.56 M AUD
Jan 1, 2020
-11.81 M AUD
Jan 1, 2021
83.36 M AUD
Jan 1, 2022
59.51 M AUD
Jan 1, 2023
71.46 M AUD
Jan 1, 2024
70.93 M AUD
Jan 1, 2025
64.24 M AUD
Jan 1, 2026
170.16 M AUD
The 4DMedical Equity history
YEAREquityYoY
170.16 MAUD+164.91%
64.24 MAUD-9.43%
70.93 MAUD-0.75%
71.46 MAUD+20.08%
59.51 MAUD-28.61%
83.36 MAUD-805.82%
-11.81 MAUD-359.23%
4.56 MAUD+20.58%
3.78 MAUD+16.27%
3.25 MAUD+254.80%
915,873.00AUD+71.86%
532,933.00AUD0.00%
532,933.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4DMedical Stock analysis

What does 4DMedical do? 4DMedical Ltd. commercializes its XV Technology, a four-dimensional lung imaging platform, through FDA-cleared XV Lung Ventilation Analysis Software (XV LVA) and CT LVAS, delivered via a software-as-a-service model. The company sells these products to hospitals and clinics, including I-MED Radiology Network, which operates approximately 250 clinics nationwide. XV LVAS and CT LVAS reports are generated using the company’s software, leveraging existing hospital imaging equipment or the XV Scanner. The firm’s revenue comes from SaaS subscriptions and software licensing for its imaging solutions. I-MED Radiology Network is a key client, with 4DMedical initiating the commercial rollout of XV LVAS within its network. The company provides lung imaging technology to selected clinics across I-MED, utilizing the XV Scanner or existing hospital equipment. Revenue streams are derived from the SaaS delivery model, with no mention of additional products or services beyond XV LVA and CT LVAS. 4DMedical’s flagship technology powers dynamic lung ventilation analysis, enabling physicians to identify respiratory issues earlier. The company’s products are designed for use with existing hospital imaging systems, reducing the need for additional hardware. The primary buyers are medical imaging providers like I-MED, which integrate XV Technology into their diagnostic services for respiratory conditions. 4DMedical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing 4DMedical's Equity

4DMedical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding 4DMedical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating 4DMedical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

4DMedical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in 4DMedical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about 4DMedical stock

The Equity of 4DMedical is 170.16 M AUD in 2026.

The Equity of 4DMedical changed from 64.24 M AUD to 170.16 M AUD, representing a 164.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity 4DMedical since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's 4DMedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 4DMedical

All Key Metrics — 4DMedical